UW Department of Ophthalmology: GLAUCOMA CLINICAL TRIALS

Glaucoma Clinical Trials

The Collaborative Initial Glaucoma Treatment Study (CIGTS) is a randomized, multicenter clinical trial, designed to determine whether patients with newly diagnosed open-angle glaucoma are better treated by initial treatment with medication or by immediate filtration surgery. It was previously funded by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and recuitment ended in 1997 with 607 patients enrolled nationwide. Initial results showed no difference in outcome between the two arms, based on traditional ophthalmic measures as well as patients' health-related quality of life outcomes, but follow up continues. Philip P. Chen, M.D., Principal Investigator, Raghu Mudumbai, M.D., Co-Investigator, and Patricia Ernst, COA, study coordinator, follow the patients in this study.

The Memantine Phase 3 Study of Open Angle Glaucoma Patients is a randomized, multicenter,placebo-controlled, double-masked clinical trial, designed to determine whether memantine, an oral medication, is useful for prevention of progression of open angle glaucoma. It is funded by Allergan Corporation, and recruitment ended in 2001 with more than 500 patients in this study. Study procedures and follow up continue, and no results have yet been released. Philip P. Chen, M.D., Prinicipal Investigator, Raghu Mudumbai, M.D., Co-Investigator, and Patricia Ernst, COA, study coordiantor, follow the patients in this study.

				AIDS-related Clinical Trials Other Clinical Trials
	Glaucoma Clinical Trials The Collaborative Initial Glaucoma Treatment Study (CIGTS) is a randomized, multicenter clinical trial, designed to determine whether patients with newly diagnosed open-angle glaucoma are better treated by initial treatment with medication or by immediate filtration surgery. It was previously funded by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and recuitment ended in 1997 with 607 patients enrolled nationwide. Initial results showed no difference in outcome between the two arms, based on traditional ophthalmic measures as well as patients' health-related quality of life outcomes, but follow up continues. Philip P. Chen, M.D., Principal Investigator, Raghu Mudumbai, M.D., Co-Investigator, and Patricia Ernst, COA, study coordinator, follow the patients in this study. The Memantine Phase 3 Study of Open Angle Glaucoma Patients is a randomized, multicenter,placebo-controlled, double-masked clinical trial, designed to determine whether memantine, an oral medication, is useful for prevention of progression of open angle glaucoma. It is funded by Allergan Corporation, and recruitment ended in 2001 with more than 500 patients in this study. Study procedures and follow up continue, and no results have yet been released. Philip P. Chen, M.D., Prinicipal Investigator, Raghu Mudumbai, M.D., Co-Investigator, and Patricia Ernst, COA, study coordiantor, follow the patients in this study.